INVA — Innoviva, Inc.
$19.03
+$0.06 (+0.32%)
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
Market Cap
$1.35B
Forward P/E
8.6x
52-Week Range
N/A
INVA Price History
Revenue vs. Net Income
$411M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$186M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
21.7%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.5x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2.6%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+14.3%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
